Cantor Fitzgerald Decreases Earnings Estimates for Affimed

Affimed (NASDAQ:AFMD) – Cantor Fitzgerald reduced their FY2024 earnings estimates for shares of Affimed in a research report issued to clients and investors on Tuesday, November 19th. Cantor Fitzgerald analyst L. Watsek now expects that the biopharmaceutical company will post earnings of ($4.06) per share for the year, down from their previous forecast of ($3.71). Cantor Fitzgerald has a “Overweight” rating on the stock. The consensus estimate for Affimed’s current full-year earnings is ($3.91) per share.

Affimed (NASDAQ:AFMD) last released its quarterly earnings data on Thursday, September 5th. The biopharmaceutical company reported ($1.09) earnings per share (EPS) for the quarter, missing the consensus estimate of ($1.00) by ($0.09). Affimed had a negative return on equity of 193.84% and a negative net margin of 7,836.26%. The firm had revenue of $0.17 million for the quarter, compared to analysts’ expectations of $1.67 million.

AFMD has been the subject of several other reports. Stifel Nicolaus dropped their target price on shares of Affimed from $5.00 to $4.00 and set a “hold” rating for the company in a report on Friday, November 15th. HC Wainwright reaffirmed a “buy” rating and issued a $10.00 target price on shares of Affimed in a research report on Friday, November 15th. One investment analyst has rated the stock with a sell rating, one has assigned a hold rating and four have issued a buy rating to the stock. According to data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and a consensus price target of $16.00.

Affimed Price Performance

Shares of NASDAQ AFMD opened at $2.64 on Friday. Affimed has a 1-year low of $2.64 and a 1-year high of $8.95. The stock has a fifty day moving average price of $3.43 and a 200 day moving average price of $4.47. The company has a quick ratio of 1.93, a current ratio of 1.93 and a debt-to-equity ratio of 0.13.

Institutional Investors Weigh In On Affimed

Several institutional investors and hedge funds have recently modified their holdings of AFMD. Jane Street Group LLC bought a new position in Affimed in the 3rd quarter worth approximately $44,000. Point72 Asset Management L.P. increased its holdings in shares of Affimed by 4.6% during the 3rd quarter. Point72 Asset Management L.P. now owns 342,856 shares of the biopharmaceutical company’s stock worth $1,152,000 after purchasing an additional 15,108 shares during the period. FMR LLC grew its position in Affimed by 30.0% during the third quarter. FMR LLC now owns 17,696 shares of the biopharmaceutical company’s stock worth $59,000 after buying an additional 4,086 shares in the last quarter. Intellectus Partners LLC raised its holdings in Affimed by 12.2% in the 3rd quarter. Intellectus Partners LLC now owns 94,361 shares of the biopharmaceutical company’s stock valued at $317,000 after acquiring an additional 10,250 shares in the last quarter. Finally, Choreo LLC bought a new stake in shares of Affimed during the second quarter valued at approximately $54,000. Institutional investors and hedge funds own 30.82% of the company’s stock.

About Affimed

Affimed N.V., a clinical-stage biopharmaceutical company, focuses on discovering and developing cancer immunotherapies in the United States and Germany. The company’s lead product candidates include AFM13 that has completed Phase 2 clinical trial for CD30-positive lymphoma, Phase Ib clinical trial for hodgkin lymphoma, and completed Phase IIb clinical study for peripheral T-cell lymphoma; AFM24, a tetravalent, bispecific epidermal growth factor receptor, and CD16A-binding innate cell engager, which is in Phase IIa clinical trial for the treatment of advanced cancers; and AFM28, an innate cell engager (ICE), which is in preclinical development for the treatment acute myeloid.